A Study of LY2189265 in Japanese Patients With Type 2 Diabetes

Summary

The main purpose of this study is to assess dose-response characteristics in Japanese patients with Type 2 Diabetes taking LY2189265 monotherapy.

Timeline

Start

2009-10

Primary completion

2010-12

Completion

2010-12

Outcome

Met primary endpoint

registry analysis (superiority or other test); 0.75 mg LY2189265 vs Placebo; p <0.001; Least Squares Mean Difference -1.17; Mixed Models Analysis NCT01001104 ↗

Drugs

Indications